# SWITCH (NCT06649331)

> Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06649331
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Fudan University
- Conditions: Advanced Breast Cancer; Metastatic Breast Cancer; Triple Negative Breast Cancer (TNBC); HER2-negative Breast Cancer; Breast Cancer
- Interventions: SHR-A1811; SHR-A1921; SHR-A2009; SHR-A2102; Famitinib; Fat Module Formula for Special Medical Purposes; Trastuzumab (or biosimilar); 9MW2821; Disitamab Vedotin (RC48); Treatment of physician's choice (TPC)
- Enrollment: 160
- Primary outcome: Objective response rate (ORR)

## Indexed commentary on SWITCH so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 7

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=switch-nct06649331